Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
CSTLCastle Biosciences(CSTL) Businesswire·2024-01-14 17:30

Castle Biosciences产品展示 - Castle Biosciences将在2024年冬季临床皮肤病学会议上展示其皮肤病学产品组合的新数据[1] DecisionDx-Melanoma基因表达谱测试 - DecisionDx-Melanoma基因表达谱测试结果与临床和病理因素结合，为皮肤癌患者提供更个性化、精准的肿瘤复发风险评估[3] DecisionDx-SCC基因表达谱测试 - DecisionDx-SCC基因表达谱测试可独立提高对低分期肿瘤转移风险的识别，为临床决策提供更准确的风险评估[3]